CRISPR pioneer Feng Zhang is building a new gene-editing startup, Insider has learned.
CRISPR pioneer Feng Zhang is in the process of launching yet another ambitious gene-editing startup, backed by approximately $200 million from some of biotech's biggest investors, Insider has exclusively learned.
Aera was incorporated in September 2021, shortly after Zhang's research was published in Science.
Aera is at least the seventh startup Zhang has cofounded, joining a list that includes base-editing biotech Beam Therapeutics, CRISPR company Editas Medicine, and gene-editing startup Arbor Biotechnologies.
While the ARC protein seems tailored for brain delivery, Zhang's suite of proteins could reach other organs, Shepherd said.